Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intrathecal Administration of PD-1/CTLA-4 Bispecific Antibody Plus Pemetrexed in Patients With Leptomeningeal Metastasis From Solid Tumors: A Phase I/II Study

NCT06762080 is registered in ClinicalTrials.gov with Guangzhou Medical University as lead sponsor.

NCT NCT06762080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06762080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intrathecal Administration of PD-1/CTLA-4 Bispecific Antibody Plus Pemetrexed in Patients With Leptomeningeal Metastasis From Solid Tumors: A Phase I/II Study
Lead sponsor
Guangzhou Medical University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 7, 2025
Completion date
October 30, 2026
Enrollment
39 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal metastasis